This is a blend. TB-500, KPV and BPC-157 are combined in a single 30 mg vial, 10 mg of each. All three appear in tissue and inflammation research, but they work through different routes. TB-500 has been studied at actin, a protein that lets cells change shape and move. KPV has been studied at NF-kB, a signalling pathway involved in inflammation. BPC-157 has been studied at growth factor pathways and blood vessel formation. Researchers use blends to compare combined conditions against single compounds.
The numbers that define TB-500 / KPV / BPC-157 and how it is being studied. For laboratory research use only.
3
Research Peptides
TB-500 · KPV · BPC-157
30 mg
Total Per Vial
10 mg of each component
NF-κB
KPV Pathway Target
Inflammatory signalling regulator
4
Research Areas
Tendon & Ligament
Intestinal Inflammation
Wound Closure
How It Works
How TB-500 / KPV / BPC-157 works
The pathways TB-500 / KPV / BPC-157 acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Cell Migration & Actin Regulation
TB-500
TB-500 sequesters G-actin monomers, with cytoskeletal remodelling and cell migration toward injury sites measured. Integrin-linked kinase (ILK) signalling is also characterised.
Actin-mediated cell migration
Integrin-linked kinase activation
Anti-fibrotic remodeling
Inflammatory Pathway Suppression
KPV
KPV is the C-terminal tripeptide of α-MSH. At nanomolar concentrations, lower NF-κB and MAP-kinase pathway activation is measured in vitro, alongside reduced TNF-α, IL-6 and IL-1β secretion. Cellular uptake runs through the PepT1 transporter.
NF-κB and MAP-kinase inhibition measured
Lower pro-inflammatory cytokines measured
PepT1-mediated cellular uptake
Angiogenesis & Cytoprotection
BPC-157
Raised VEGF expression and new vessel formation have been measured for BPC-157, alongside perfusion of the surrounding tissue. NO system activity and cytoprotective endpoints are also characterised.
VEGF-mediated angiogenesis
Nitric oxide system modulation
Gastric and tissue cytoprotection
Uses & Applications
What TB-500 / KPV / BPC-157 is researched for
The main areas TB-500 / KPV / BPC-157 is being studied for - and the study-reported figures behind them.
Musculoskeletal
Tendon & Ligament
BPC-157 is studied in tendon models while TB-500 is characterised for cell migration toward the injury site; KPV adds an inflammatory-signalling arm to the combined condition.
Gastroenterology
Intestinal Inflammation Models
KPV lowered intestinal inflammation scores in DSS- and TNBS-induced colitis models, and BPC-157 is studied for gastric and intestinal cytoprotection.
Dermatology
Wound Closure Models
TB-500 is studied in dermal and scarring models, BPC-157 for perfusion at wound sites, and KPV for epithelial re-closure in a corneal model.
Anti-Inflammatory
Inflammatory Signalling
Anti-inflammatory endpoints are measured for all three peptides through distinct mechanisms: actin regulation, NF-κB inhibition and the NO system.
Study-reported magnitudes
Representative figures from published research. Bars fill as you scroll.
TB-500 Cell Migration85%
KPV NF-κB ActivationInhibited
BPC-157 Tendon Remodelling72%
KPV Colitis Severity (DSS / TNBS models)Scored
Figures are representative of published research findings and shown for reference.
Molecular Structure
The TB-500 / KPV / BPC-157 molecule
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
Sequence length
blend
Physical form
Lyophilized powder blend
Documented purity
≥99% by HPLC
Compound Information
Full specification
Components
TB-500 (Thymosin Beta-4) + KPV + BPC-157
Content
30 mg per vial (10 mg of each component)
TB-500 Fragment
43-amino acid active region of Tβ4
KPV Sequence
Lys-Pro-Val (α-MSH 11-13)
BPC-157 Sequence
15 amino acids (Gly-Glu-Pro-Pro-Pro...)
Form
Lyophilized powder blend
Purity
≥99% per component (HPLC verified)
Testing
Third-party HPLC, Mass Spec, Endotoxin
Storage
-20°C for long-term stability
Solubility
Water-soluble
COA
Included with every order
FAQ
Common questions about TB-500 / KPV / BPC-157
The three peptides act through complementary mechanisms. Cell mobilisation via actin regulation is measured for TB-500, NF-κB inhibition for KPV, and vessel formation and perfusion for BPC-157. The combination covers cellular-migration, inflammatory-signalling and vascular pathways.
BPC-157 / TB-500 is a two-peptide blend. This blend adds KPV for an inflammatory-signalling arm. KLOW is a four-peptide blend that also includes GHK-Cu.
No. The combination has not been characterised as a single formulation. The rationale is based on mechanisms described for each component individually in preclinical models.
No. None of TB-500, KPV or BPC-157 is FDA approved for any indication. This blend is sold exclusively for in vitro laboratory research purposes and is not intended for human consumption.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.
